Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.69 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.60 |
| ▸ | KDM1A | O60341 | 2/20 | 0.58 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.57 |
| ▸ | GLP1R | P43220 | 1/20 | 0.57 |
| ▸ | GCGR | P47871 | 1/20 | 0.57 |
| ▸ | GIPR | P48546 | 1/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471608 | 0.98 | TFPI (0.65) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL13540733 | 0.98 | TFPI (0.65) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL13540736 | 0.97 | TFPI (0.68) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL13540742 | 0.96 | TFPI (0.65) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL15235437 | 0.95 | TFPI (0.62) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL15235440 | 0.94 | TFPI (0.62) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL14822780 | 0.94 | TFPI (0.62) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL16706481 | 0.93 | TFPI (0.60) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL15235439 | 0.93 | VIPR1 (0.63) | TFPIVIPR1KDM1AVIPR2GLP1R | |
| SCHEMBL15471605 | 0.93 | TFPI (0.69) | TFPIVIPR1VIPR2GLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181301-B2 | TDF-related compounds and analogs thereof | THRASOS INNOVATION, INC. (CA) | 2015-11-10 | — | — | US | disclosed |
| US-20150132355-A1 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF | THRASOS, INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150132355-A1 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF | PGF, EDF1, DCTD | TFPI 149/4885VIPR1 975/4885KDM1A 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.